[Clinical and functional aspects of the World Health Organization histologic classification of thymic epithelial tumors].
The World Health Organization (WHO) histologic classification was presented by the international committee to provide a universal system for clinicians and researchers in 1999 and was further modified in 2004. This classification is mainly based on Müller-Hermelink et al.'s system and six distinct types were defined. Thymomas were classified into type A, AB, B1, B2, and B3 tumors, according to the shape and atypia of epithelial cells and also the abundance of lymphocytes. Another type of tumor is thymic carcinomas, which have apparent atypia of neoplastic cells. Neuroendocrine tumor (carcinoid) of the thymus was categorized as thymic carcinoma because of the resemblance of genetic aberrations. Several studies have shown that the WHO histologic type is correlated with the proportion of invasive tumors and is an independent prognostic factor along with Masaoka stage. Furthermore, association with myasthenia gravis, ability to induce CD4+CD8+T cells and express HLA-DR molecules, and chromosomal imbalances such as loss of heterogeneity were found to be correlated with the WHO histologic type. Thus, the WHO histologic classification system reflects the oncologic, immunologic, and genetic characteristics of thymic epithelial tumors. The clinical application of this classification system is expected.
Okumura
Meinoshin
M
Department of Surgery, Osaka University Graduate School of Medicine, Suita, Japan.
Shiono
Hiroyuki
H
Inoue
Masayoshi
M
Sawa
Yoshiki
Y
D002277:Carcinoma / Q000145:classification* / Q000235:genetics / Q000276:immunology / Q000473:pathology*; D002872:Chromosome Deletion; D006801:Humans; D009157:Myasthenia Gravis / Q000209:etiology; D013953:Thymus Neoplasms / Q000145:classification* / Q000235:genetics / Q000276:immunology / Q000473:pathology*; D014944:World Health Organization